SEC Form 4 · accession 0001104659-18-032900
SUPERNUS PHARMACEUTICALS, INC. · SUPN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Padmanabh P. Bhatt
Officer — Sr. VP of IP, CSO
Period of report
May 10, 2018
Accepted (ET)
May 14, 2018 · 3:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001356576
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 10, 2018 | M | 20,000 | $7.90 | A | 32,500 | D | |
| Common StockF2 | May 10, 2018 | S | 20,000 | $49.8772 | D | 12,500 | D | |
| Common Stock | May 11, 2018 | M | 20,000 | $7.90 | A | 32,500 | D | |
| Common StockF3 | May 11, 2018 | S | 20,000 | $52.0279 | D | 12,500 | D | |
| Common Stock | May 11, 2018 | M | 11,250 | $9.24 | A | 23,750 | D | |
| Common StockF4 | May 11, 2018 | S | 16,250 | $55.2334 | D | 7,500 | D | |
| Common Stock | May 11, 2018 | M | 10,882 | $9.24 | A | 18,382 | D | |
| Common Stock | May 11, 2018 | S | 10,882 | $57.90 | D | 7,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F5 | $7.90 | May 10, 2018 | M | 20,000 | D | — | Feb 5, 2023 | Common Stock | 20,000 | 20,000 | D |
| Employee Stock Option (Right to Buy)F5 | $7.90 | May 11, 2018 | M | 20,000 | D | — | Feb 5, 2023 | Common Stock | 20,000 | 0 | D |
| Employee Stock Option (Right to Buy)F6 | $9.24 | May 11, 2018 | M | 11,250 | D | — | Jan 21, 2024 | Common Stock | 11,250 | 18,750 | D |
| Employee Stock Option (Right to Buy)F6 | $9.24 | May 11, 2018 | M | 10,882 | D | — | Jan 21, 2024 | Common Stock | 10,882 | 7,868 | D |
Explanation of responses
- F1Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.8500 to $49.9500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.8500 to $52.2750, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.8500 to $55.5000, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
- F5The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted.
- F6The option became exercisable in four equal installments beginning on January 21, 2015, which was the first anniversary of the date on which the option was granted.